+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Manking Pharma launches drug for treatment of infertility in India

Dec 5, 2019, 15:12 IST
PTI
New Delhi, Dec 5 () Drug firm Mankind Pharma on Thursday said it has launched its generic Dydrogesterone tablets for treatment of infertility and pregnancy related complications in the Indian market.

With the launch, the company has become the first Indian and second global firm to develop the drug, Mankind Pharma said in a statement.

Advertisement

The company's product is generic version of Abbott's Duphaston tablets, it added.

The manufacturing process of Dydrogesterone is very complex as it involves conversion of natural progesterone, the statement said.

Progesterone is a natural hormone involved in menstrual cycle, implantation and in successful maintenance of pregnancy.

Any deficiency of progesterone during different stages of reproductive process can cause infertility, menstrual disorders and miscarriage, it added.

Advertisement

"The launch of this drug is an important milestone for Mankind Pharma. We are the first Indian pharmaceutical company to develop this drug and second company in the world," Mankind Group founder and Chairman R C Juneja said.

Currently the drug is being launched only in India, post that the company is planning to launch the drug in countries where it already has a presence, he added.

Mankind has a strong presence in pharmaceutical, veterinary, OTC & FMCG segments.

The company is present across North America, Asia, Africa and CIS countries. AKT RVK

(This story has not been edited by www.businessinsider.in and is auto–generated from a syndicated feed we subscribe to.)
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article